Virulizin, a novel immunotherapy agent, activates NK cells through induction of IL-12 expression in macrophages

Cancer Immunology, Immunotherapy

Volumn 54, Issue 11, 2005, Pages 1115-1126

  Li, Hui ^a   Cao, Ming Y ^a   Lee, Yoon ^a   Lee, Vivian ^a   Feng, Ningping ^a   Benatar, Tania ^a   Jin, Hongnan ^a   Wang, Ming ^a   Der, Sandy ^b   Wright, Jim A ^a   Young, Aiping H ^a  

^a Lorus Therapeutics Inc   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cancer; IL 12; Immunotherapy; Macrophage; NK cytotoxicity; Virulizin

Indexed keywords

CD1 ANTIGEN; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 12BETA; INTERLEUKIN DERIVATIVE; MESSENGER RNA; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRULIZIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; MACROPHAGE; MELANOMA CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN INDUCTION; SPLEEN CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BILE; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; INTERLEUKIN-12; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; NEOPLASM TRANSPLANTATION; RNA, MESSENGER; TISSUE EXTRACTS; TRANSPLANTATION, HETEROLOGOUS;

EID: 25844494242     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0698-x     Document Type: Article

References (55)

1. Du C, Feng N, Jin H, Lee V, Wang M, Wright JA, Young AH (2003) Macrophages play a critical role in the anti-tumor activity of Virulizin. Int J Oncol 23:1341-1346
2. Liu C, Ferdinandi ES, Ely G, Joshi SS (2000) Virulizin-2gamma, a novel immunotherapeutic agent, in treatment of human pancreatic cancer xenografts. Int J Oncol 16:1015-1020
3. Feng N, Jin H, Wang M, Du C, Wright JA, Young AH (2003) Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts. Cancer Chemother Pharmacol 51:247-255
4. Ferdinandi ES, Braun DP, Liu C, Zee BC, Ely G (1999) Virulizin(R) - a review of its antineoplastic activity. Expert Opin Investig Drugs 8:1721-1735
5. Cao MY, Lee Y, Feng N, Li H, Du C, Miao D, Li J, Lee V, Jin H, Wang M, Gu X, Wright JA, Young AH (2005) NK cell activation and tumor infiltration are involved in the antitumor mechanism of Virulizin. Cancer Immunol Immunother 54:229-242
6. Whiteside TL, Herberman RB (1995) The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol 7:704-710
7. Smyth MJ, Hayakawa Y, Takeda K, Yagita H (2002) New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2:850-861
8. Albertsson PA, Basse PH, Hokland M, Goldfarb RH, Nagelkerke JF, Nannmark U, Kuppen PJ (2003) NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol 24:603-609
9. Ljunggren HG, Karre K (1985) Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med 162:1745-1759
10. Karre K, Ljunggren HG, Piontek G, Kiessling R (1986) Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319:675-678
11. van den Broek MF, Kagi D, Zinkernagel RM, Hengartner H (1995) Perform dependence of natural killer cell-mediated tumor control in vivo. Eur J Immunol 25:3514-3516
12. Smyth MJ, Thia KY, Cretney E, Kelly JM, Snook MB, Forbes CA, Scalzo AA (1999) Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol 162:6658-6662
13. Yu TK, Caudell EG, Smid C, Grimm EA (2000) IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway. J Immunol 164:6244-6251
14. Frederick M, Grimm E, Krohn E, Smid C, Yu TK (1997) Cytokine-induced cytotoxic function expressed by lymphocytes of the innate immune system: distinguishing characteristics of NK and LAK based on functional and molecular markers. J Interferon Cytokine Res 17:435-447
15. Herberman RB, Reynolds CW, Ortaldo JR (1986) Mechanism of cytotoxicity by natural killer (NK) cells. Annu Rev Immunol 4:651-680
16. Smyth MJ, Taniguchi M, Street SE (2000) The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol 165:2665-2670
17. Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, Croce CM, Baumann H, Caligiuri MA (1997) A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 99:937-943
18. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, Anderson D, Eisenmann J, Grabstein K, Caligiuri MA (1994) Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 180:1395-1403
19. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G (1989) Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170:827-845
20. Chan SH, Perussia B, Gupta JW, Kobayashi M, Pospisil M, Young HA, Wolf SF, Young D, Clark SC, Trinchieri G (1991) Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med 173:869-879
21. Kodama T, Takeda K, Shimozato O, Hayakawa Y, Atsuta M, Kobayashi K, Ito M, Yagita H, Okumura K (1999) Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur J Immunol 29:1390-1396
22. Nanni P, Rossi I, De Giovanni C, Landuzzi L, Nicoletti G, Stoppacciaro A, Parenza M, Colombo MP, Lollini PL (1998) Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. Cancer Res 58:1225-1230
23. Fan X, Sibalic V, Niederer E, Wuthrich RP (1996) The proinflammatory cytokine interleukin-12 occurs as a cell membrane-bound form on macrophages. Biochem Biophys Res Commun 225:1063-1067
24. Kato T, Yamane H, Nariuchi H (1997) Differential effects of LPS and CD40 ligand stimulations on the induction of IL-12 production by dendritic cells and macrophages. Cell Immunol 181:59-67
25. Blotta MH, DeKruyff RH, Umetsu DT (1997) Corticosteroids inhibit IL-12 production in human monocytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes. J Immunol 158:5589-5595
26. Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V, Bals R, Giese T, Engelmann H, Endres S, Krieg AM, Hartmann G (2001) Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 31:3026-3037
27. Kang K, Kubin M, Cooper KD, Lessin SR, Trinchieri G, Rook AH (1996) IL-12 synthesis by human Langerhans cells. J Immunol 156:1402-1407
28. Yawalkar N, Limat A, Brand CU, Braathen LR (1996) Constitutive expression of both subunits of interleukin-12 in human keratinocytes. J Invest Dermatol 106:80-83
29. Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133-146
30. van Rooijen N, van Kesteren-Hendrikx E (2003) "In vivo" depletion of macrophages by liposome-mediated "suicide". Methods Enzymol 373:3-16
31. Costello RT, Fauriat C, Sivori S, Marcenaro E, Olive D (2004) NK cells: innate immunity against hematological malignancies? Trends Immunol 25:328-333
32. Shaw SG, Maung AA, Steptoe RJ, Thomson AW, Vujanovic NL (1998) Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy. J Immunol 161:2817-2824
33. Smith DL, Cai J, Zhu S, Wei W, Fukumoto J, Sharma S, Masood R, Gill PS (2003) Natural killer cell cytolytic activity is necessary for in vivo antitumor activity of the dipeptide L-glutamyl-L-tryptophan. Int J Cancer 106:528-533
34. Ahlberg R, MacNamara B, Andersson M, Zheng C, Svensson A, Holm G, Hansson M, Porwit-MacDonald A, Bjorkholm M, Sundblad A (2003) Stimulation of T-cell cytokine production and NK-cell function by IL-2, IFN-alpha and histamine treatment during remission of non-Hodgkin's lymphoma. Hematol J 4:336-341
35. Lehmann C, Zeis M, Uharek L (2001) Activation of natural killer cells with interleukin 2 (IL-2) and IL-12 increases perforin binding and subsequent lysis of tumour cells. Br J Haematol 114:660-665
36. Trinchieri G (1998) Proinflammatory and immunoregulatory functions of interleukin-12. Int Rev Immunol 16:365-396
37. Wolf SF, Temple PA, Kobayashi M, Young D, Dicig M, Lowe L, Dzialo R, Fitz L, Ferenz C, Hewick RM et al (1991) Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 146:3074-3081
38. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK (1993) Antitumor and anti-metastatic activity of interleukin 12 against murine tumors. J Exp Med 178:1223-1230
39. Zou JP, Yamamoto N, Fujii T, Takenaka H, Kobayashi M, Herrmann SH, Wolf SF, Fujiwara H, Hamaoka T (1995) Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol 7:1135-1145
40. Trinchieri G (1995) Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13:251-276
41. Sugaya M, Nakamura K, Tamaki K (1999) Interleukins 18 and 12 synergistically upregulate interferon-gamma production by murine dendritic epidermal T cells. J Invest Dermatol 113:350-354
42. Tominaga K, Yoshimoto T, Torigoe K, Kurimoto M, Matsui K, Hada T, Okamura H, Nakanishi K (2000) IL-12 synergizes with IL-18 or IL-1beta for IFN-gamma production from human T cells. Int Immunol 12:151-160
43. Puddu P, Fantuzzi L, Borghi P, Varano B, Rainaldi G, Guillemard E, Malorni W, Nicaise P, Wolf SF, Belardelli F, Gessani S (1997) IL-12 induces IFN-gamma expression and secretion in mouse peritoneal macrophages. J Immunol 159:3490-3497
44. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J (1995) Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87:581-586
45. Brombacher F, Kastelein RA, Alber G (2003) Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol 24:207-212
46. Trapani JA, Davis J, Sutton VR, Smyth MJ (2000) Proapoptotic functions of cytotoxic lymphocyte granule constituents in vitro and in vivo. Curr Opin Immunol 12:323-329
47. Shresta S, Pham CT, Thomas DA, Graubert TA, Ley TJ (1998) How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol 10:581-587
48. Berke G (1994) The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects. Annu Rev Immunol 12:735-773
49. Vujanovic NL, Nagashima S, Herberman RB, Whiteside TL (1996) Nonsecretory apoptotic killing by human NK cells. J Immunol 157:1117-1126
50. Henkart PA, Sitkovsky MV (1994) Cytotoxic lymphocytes. Two ways to kill target cells. Curr Biol 4:923-925
51. Kelly JM, Darcy PK, Markby JL, Godfrey DI, Takeda K, Yagita H, Smyth MJ (2002) Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol 3:83-90
52. Moretta A, Bottino C, Mingari MC, Biassoni R, Moretta L (2002) What is a natural killer cell? Nat Immunol 3:6-8
53. Salcedo TW, Azzoni L, Wolf SF, Perussia B (1993) Modulation of perform and granzyme messenger RNA expression in human natural killer cells. J Immunol 151:2511-2520
54. Uharek L, Zeis M, Glass B, Steinmann J, Dreger P, Gassmann W, Schmitz N, Muller-Ruchholtz W (1996) High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2. Leukemia 10:1758-1764
55. Lehmann C, Zeis M, Schmitz N, Uharek L (2000) Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells. Blood 96:594-600